Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843-852.
Klein DA, Arnold JJ, Reese ES. Provision of contraception: key recommendations from the CDC. Am Fam Physician. 2015;91(9):625-633.
Practice bulletin no. 152: emergency contraception. Obstet Gynecol. 2015;126(3):e1-e11.
Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1-66.
Hatcher RA. Contraceptive Technology. 21st ed. Ayer Company Publishers, Inc.; 2018.
Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med. 2021;384(4):335-344.
Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019(1):CD001324.
Jatlaoui TC, Curtis KM. Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. Contraception. 2016;94(6):605-611.
Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994-2000.
- Contraceptive Technology. Comparing typical effectiveness of contraceptive methods. Accessed February 18, 2022. http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/Contraception-Effectiveness.pdf
Peragallo Urrutia R, Polis CB, Jensen ET, et al. Effectiveness of fertility awareness-based methods for pregnancy prevention: a systematic review [published correction appears in Obstet Gynecol. 2019; 133(2): 382]. Obstet Gynecol. 2018;132(3):591-604.
Brewer M, Stevens L. Use of fertility awareness-based methods of contraception: evidence from the National Survey of Family Growth, 2013–2017. Contraception. 2021;104(2):183-187.
Webb S, Cheng A, Simmons R, et al. A mixed-methods assessment of health care providers' knowledge, attitudes, and practices around fertility awareness-based methods in Title X clinics in the United States. Womens Health Rep (New Rochelle). 2020;1(1):354-365.
Polis CB. Published analysis of contraceptive effectiveness of Daysy and DaysyView app is fatally flawed. Reprod Health. 2018;15(1):113.
Duane M, Contreras A, Jensen ET, et al. The performance of fertility awareness-based method apps marketed to avoid pregnancy. J Am Board Fam Med. 2016;29(4):508-511.
U.S. Food and Drug Administration. FDA allows marketing of first direct-to-consumer app for contraceptive use to prevent pregnancy. August 10, 2018. Accessed June 8, 2021. https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-direct-consumer-app-contraceptive-use-prevent-pregnancy
U.S. Food and Drug Administration. 510(k) premarket notification. Clue Birth Control. February 18, 2021. Accessed June 8, 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K193330
Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123(7):612-624.
Tepper NK, et al. Safety of hormonal contraceptives among women with migraine: a systematic review. Contraception. 2016;94(6):630-640.
Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5):489.e1-489.e7.
Etminan M, Takkouche B, Isorna FC, et al. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies [published corrections appear in BMJ. 2005; 330(7487): 345 and BMJ. 2005; 330(7491): 596]. BMJ. 2005;330(7482):63.
MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke. 2007;38(9):2438-2445.
ACOG practice bulletin no. 206: use of hormonal contraception in women with coexisting medical conditions [published correction appears in Obstet Gynecol. 2019; 133(6): 1288]. Obstet Gynecol. 2019;133(2):e128-e150.
Ti AJ, Roe AH, Whitehouse KC, et al. Effectiveness and safety of extending intrauterine device duration: a systematic review. Am J Obstet Gynecol. 2020;223(1):24-35.e3.
Thaxton L, Lavelanet A. Systematic review of efficacy with extending contraceptive implant duration. Int J Gynaecol Obstet. 2019;144(1):2-8.
Curtis KM, Peipert JF. Long-acting reversible contraception. N Engl J Med. 2017;376(5):461-468.
Secura GM, et al. Provision of no-cost, long-acting contraception and teenage pregnancy [published correction appears in N Engl J Med. 2014; 372(3): 297]. N Engl J Med. 2014;371(14):1316-1323.
ACOG committee opinion no. 735: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2018;131(5):e130-e139.
Krempasky C, Harris M, Abern L, et al. Contraception across the trans-masculine spectrum. Am J Obstet Gynecol. 2020;222(2):134-143.
Kennedy CE, Yeh PT, Gaffield ML, et al. Self-administration of injectable contraception: a systematic review and meta-analysis. BMJ Glob Health. 2019;4(2):e001350.
Bahamondes L, Fernandes A, Bahamondes MV, et al. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: a chart review of 776 women in Brazil. Contraception. 2018;97(3):205-209.
- FDA News. FDA expands approval of Mirena IUD device. August 25, 2022. Accessed August 29, 2022. https://www.fdanews.com/articles/209140-fda-expands-approval-of-mirena-iud-device
Liletta (levonorgestrel-releasing intrauterine system). Allergan, Inc.; 2019. Accessed May 31, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206229s008lbl.pdf
McNicholas C, Swor E, Wan L, et al. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol. 2017;216(6):586.e1-586.e6.
- American College of Obstetricians and Gynecologists' Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethics. Patient-centered contraceptive counseling: ACOG committee statement number 1. Obstet Gynecol. 2022;139(2):350-353.
Brandi K, Fuentes L. The history of tiered-effectiveness contraceptive counseling and the importance of patient-centered family planning care. Am J Obstet Gynecol. 2020;222(4S):S873-S877.
Committee opinion no. 602: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123(6):1398-1402.
Burke HM, Chen M, Buluzi M, et al. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial. Lancet Glob Health. 2018;6(5):e568-e578.
World Health Organization. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights. 2019. Accessed May 27, 2021. https://apps.who.int/iris/bitstream/handle/10665/325480/9789241550550-eng.pdf
Kohn JE, Simons HR, Della Badia L, et al. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception. 2018;97(3):198-204.
- National Family Planning and Reproductive Health Association. DMPA-SQ and self-administration procedures clinical protocol. November 2020. Accessed May 27, 2021. https://www.nationalfamilyplanning.org/covid-19-resource-hub
Curtis KM, Nguyen A, Reeves JA, et al. Update to U.S. selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate. MMWR Morb Mortal Wkly Rep. 2021;70(20):739-743.
State of California Health and Human Services Agency. Information regarding the use of subcutaneous depot medroxyprogesterone acetate during the 2019 novel coronavirus public health emergency. Accessed March 21, 2021. https://www.dhcs.ca.gov/Documents/COVID-19/Medi-Cal-FFS-Depo-Provera-SQ-Temp-Policy.pdf
Lopez LM, Chen M, Mullins Long S, et al. Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database Syst Rev. 2015(7):CD009849.
Kyvernitakis I, Kostev K, Nassour T, et al. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2017;28(1):291-297
Health care for transgender and gender diverse individuals: ACOG committee opinion summary, number 823. Obstet Gynecol. 2021;137(3):554-555.
Taub RL, Ellis SA, Neal-Perry G, et al. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol. 2020;223(2):229.e1-229.e8.
Light A, Wang L, Zeymo A, et al. Family planning and contraception use in transgender men. Contraception. 2018;98(4):266-269.
Agénor M, Cottrill AA, Kay E, et al. Contraceptive beliefs, decision making and care experiences among transmasculine young adults: a qualitative analysis. Perspect Sex Reprod Health. 2020;52(1):7-14.
Deutsch MB, ed. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. 2nd ed. June 2016. Accessed May 27, 2021. https://transcare.ucsf.edu/guidelines
Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline [published corrections appears in J Clin Endocrinol Metab. 2018; 103(2): 699 and J Clin Endocrinol Metab. 2018; 103(7): 2758–2759]. J Clin Endocrinol Metab. 2017;102(11):3869-3903.
Klein DA, Paradise SL, Goodwin ET. Caring for transgender and gender-diverse persons: what clinicians should know. Am Fam Physician. 2018;98(11):645-653.